The fact that Brilacidin is showing success against Covid gives hope to those studying other viral disorders but the results are not transferable and would have to be repeated against every different virus.
If Brilacidin is successful in its clinical trials I believe it will be tested as an inhaler, but that should be years away. If it is successful as an inhaler I expect it will be studied in a whole series of pulmonary disorders asthma,COPD, bronchitis,cystic fibrosis, bronchiectasis, pulmonary fibrosis and perhaps others.
GLTA,Farrell
News 
Market Data 
Discover 
